2023
Image analysis-based tumor infiltrating lymphocytes measurement predicts breast cancer pathologic complete response in SWOG S0800 neoadjuvant chemotherapy trial
Fanucci K, Bai Y, Pelekanou V, Nahleh Z, Shafi S, Burela S, Barlow W, Sharma P, Thompson A, Godwin A, Rimm D, Hortobagyi G, Liu Y, Wang L, Wei W, Pusztai L, Blenman K. Image analysis-based tumor infiltrating lymphocytes measurement predicts breast cancer pathologic complete response in SWOG S0800 neoadjuvant chemotherapy trial. Npj Breast Cancer 2023, 9: 38. PMID: 37179362, PMCID: PMC10182981, DOI: 10.1038/s41523-023-00535-0.Peer-Reviewed Original ResearchPathologic complete responseBreast cancerComplete responseTIL scoreBreast Cancer Pathologic Complete ResponseTumor-infiltrating lymphocyte scoresEvent-free survivalNeoadjuvant chemotherapy trialsLymphocyte measurementsLymphocyte scoreNeoadjuvant chemotherapyChemotherapy trialsMean pretreatmentResidual diseaseTIL quantificationPredictive valuePretreatment samplesResponse discriminationScoresStrong positive correlationPositive correlation
2022
Prediction of pathologic complete response to neoadjuvant chemotherapy in breast cancer (SWOG S0800) using image analysis-based tumor infiltrating lymphocyte measurements.
Blenman K, Fanucci K, Bai Y, Pelekanou V, Nahleh Z, Shafi S, Burela S, Barlow W, Sharma P, Thompson A, Godwin A, Rimm D, Hortobagyi G, Pusztai L. Prediction of pathologic complete response to neoadjuvant chemotherapy in breast cancer (SWOG S0800) using image analysis-based tumor infiltrating lymphocyte measurements. Journal Of Clinical Oncology 2022, 40: 594-594. DOI: 10.1200/jco.2022.40.16_suppl.594.Peer-Reviewed Original ResearchPathologic complete responseBreast cancerNeoadjuvant chemotherapyComplete responseTIL scoreResidual diseaseResponse predictive markersBetter EFSBevacizumab benefitLymphocyte measurementsTIL assessmentFree survivalPredictive markerTIL quantificationInternational guidelinesPretreatment samplesLogistic regressionCancerOutcome discriminationChemotherapyScoresContinuous scoresTumorsClinical adoptionStrong positive correlation
2009
Preliminary Comparison between AQUA and Centralised ER/PgR Analysis within the TEAM Pathology Study.
Bartlett J, Rimm D, Brookes C, Dolled-Filhart M, Robson T, van de Velde C, Billingham L, Campbell F, Hasenburg A, Hille E, Kieback D, Putter H, Markopoulos C, Christiansen J, Gustavson M, Mallon E, Meershoek-Klein Kranenburg E, Parideans R, Seynaeve C, Rea D. Preliminary Comparison between AQUA and Centralised ER/PgR Analysis within the TEAM Pathology Study. Cancer Research 2009, 69: 3045-3045. DOI: 10.1158/0008-5472.sabcs-09-3045.Peer-Reviewed Original ResearchER/PgRER expressionImmunohistochemical assaysAQUA scoreExemestane Adjuvant Multinational (TEAM) trialHigh ER expressionTeam patientsPatient prognosisAromatase inhibitorsMultinational trialOutcome dataPathology studiesCancer ResAQUA technologyIHCPreliminary dataPatientsRegression analysisPGR analysisFurther dataPgRImage analysisIncremental increaseScoresMultiple cores